Dr. Jeffrey Gelblum - Legembi Alzheimer's Drug - First Choice Neurology

Facebook LIVE recording of Dr. Jeffrey Gelblum talking about who are the best candidates for the newly FDA-approved drug, LEQEMBI. You will learn about how our comprehensive healthcare team can make sure that this drug is available to those patients who need it.

The U.S. Food and Drug Administration (FDA) recently approved a new Alzheimer’s drug, Leqembi. This milestone marks a significant step forward in the fight against Alzheimer’s and offers new hope to millions of individuals and their families who have been impacted by this devastating disease.

First Choice Neurology is the national leader in the diagnosis and treatment of Alzheimer’s disease with significant experience using newly approved medications.

Did you know that there is a new test to detect your risk of getting Alzheimer’s disease? Are you concerned that having a family history of Alzheimer’s means that you will get it too? Or is a loved one showing early signs of memory loss? If so, we can help with an Alzheimer's Risk Test.

The Alzheimer’s Risk Test is a non-invasive, genetic test that assesses the risk of cognitive decline due to Alzheimer’s disease. The test calculates an individual’s personal genetic risk from a saliva sample and analyzes a genoSCORE against specific variants in your DNA associated with Alzheimer’s disease.

#alzheimers #firstchoiceneurology #legembi

Видео Dr. Jeffrey Gelblum - Legembi Alzheimer's Drug - First Choice Neurology канала First Choice Neurology